AMIX: A Reverse Split, Nine Patients, and a Prayer

Let's start with the tell. When a company slaps a 1-for-21 reverse stock split on its own shares, it's not because business is booming. It's because the stock was circling the drain below a buck and Nasdaq was about to show it the door. Autonomix Medical did exactly that on June 24, and here we are, a few weeks later, watching the stock try to convince everyone the split was a fresh start rather than a life-support measure.

I want to like this story. I really do. Pancreatic cancer pain is one of the cruelest problems in oncology — patients often describe it as unbearable, and the existing toolkit (opioids, nerve blocks, celiac plexus ablation) is either inadequate or comes with its own brutal tradeoffs. Autonomix's pitch is a transvascular nerve-ablation device that goes in through the vasculature and knocks out the pain signal at the source. If it works, it's a genuinely important therapy. That's the bull case, and it's not nothing.

But here's where I put my skeptic hat on. The company's headline evidence right now is a post-hoc subgroup analysis from its first-in-human Proof-of-Concept 1 study. Post-hoc means: they went back after the fact and sliced the data until they found a group that looked good. And that group is... nine patients at 4-6 weeks, six patients at three months. No control arm. Symptom scores improved 14.5 points then 26 points; functionality scores rose 8 then 25. Those numbers sound impressive in a press release. They sound a lot less impressive when you remember n=6 is not a clinical trial, it's an anecdote with a spreadsheet.

None of that makes the technology fake. It makes the evidence thin — and thin evidence dressed up in bold percentage gains is exactly the kind of thing that gets momentum traders excited and long-term holders burned.

The runway problem nobody's talking about loudly enough. This is a company with $0 revenue, an EBITDA of roughly negative $17 million, ROE of -238.89%, ROA of -192.06%, and about $7 million of cash on hand as of Q3 2026 (give or take, depending on which filing you trust). That's not a balance sheet — that's a countdown clock. The company just did a warrant inducement raising $2.6 million, which tells you plenty about how urgently it needs cash and how little leverage it has to raise it on favorable terms. Expect more dilution. Expect it soon.

And the regulatory timeline doesn't do the bulls any favors either. Following the FDA pre-submission meeting back in May 2025, the plan was GLP 90- and 180-day studies, an Early Feasibility Study supposedly kicking off in H1 2026, and a De Novo approval target of... 2028. That's not a catalyst-rich near-term story. That's a "come back in two years and see if we're still solvent" story.

Technically, the chart is a mess of contradictions. Yes, there was a 17.8% weekly pop and a break above $3.44. Yes, some forecast models are throwing around numbers like $7.16 short-term and a genuinely absurd $47.50 long-term target. But the 20-day and 50-day moving averages are down 27% and 48% respectively — that's a stock in a serious downtrend that just had one loud week. The 52-week low of $2.44 is the line in the sand. Break that, and the "reverse split relief rally" narrative is dead.

So where does that leave a rational trader? Honestly, in TRIM territory, and I don't think that's controversial. The internal read here lands on low conviction with a base target around $3.80, a bear case at $2.50, and a bull case at $5 over six months — which tells you even the optimistic scenario isn't asking you to believe in a moonshot, just a bounce.

My take: AMIX is a legitimate science story wrapped in a terrible balance sheet, wearing a reverse split like a bad toupee. The unmet medical need is real. The nine-patient data set is not proof of anything except that somebody's marketing team knows how to write a press release. Until there's a controlled trial, a funded runway, and a regulatory pathway that doesn't stretch to 2028, this is a trade for people who like volatility, not an investment for people who like sleeping at night.

Watch $2.44. Everything above it is a story. Everything below it is a warning.